

Ticker	Name	Market_Cap	Volume	Beta	Daily_Volatility	Latest_Share_Price	Insiders_Buying	Institutions_Buying	Stage	Sector	Industry	Drug_Name	FDA-Approved_Drug/Drugs	FDA_Fast_Track_Designations	Catalysts_Date
ABCL	AbCellera Biologics Inc.	730M	1.5M	2.13	2.5% - 7%	\$2.49 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Clinical	Healthcare	Biotechnology	ABCL-001 ABCL-002	None	None	Phase 1 Data Readout Q4 2025
ABEO	Abeona Therapeutics Inc.	210M	350K	1.89	3% - 8%	\$5.12 - 01:30 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	EB-101 Pz-cel	None	Pz-cel Fast Track 2019	Phase 3 Data Readout Q2 2026
ABSI	Absci Corporation	450M	900K	2.45	3.5% - 9%	\$4.85 - 01:30 PM EDT 06/10/2025	No	Increase	Pre-Clinical	Healthcare	Biotechnology	ABSI-101	None	None	None
ABUS	Arbutus Biopharma Corporation	650M	1.2M	1.95	2.8% - 7.5%	\$3.45 - 01:30 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	Imdusiran	None	None	Phase 2 Data Readout Q3 2026
ACAD	ACADIA Pharmaceuticals Inc.	2.8B	1.1M	1.34	2% - 6%	\$15.20 - 01:30 PM EDT 06/10/2025	Yes - Large Purchase	Increase	Commercial	Healthcare	Biotechnology	NUPLAZID DAYBUE	NUPLAZID Apr 2016 DAYBUE Mar 2023	NUPLAZID Fast Track 2014	Phase 3 Data Readout ACP-101 Q1 2026
ACET	Adicel Bio Inc.	150M	400K	1.78	3.2% - 8.5%	\$1.40 - 01:30 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare	Biotechnology	ADI-001	None	None	Phase 1 Data Readout Q4 2025
ACXL	Accellx Inc.	1.9B	500K	1.65	2.5% - 7%	\$55.30 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Clinical	Healthcare	Biotechnology	Anito-cel	None	Anito-cel Fast Track 2023	Phase 2 Data Readout Q3 2026
ACRS	Aclaris Therapeutics Inc.	90M	600K	1.92	3% - 8%	\$1.15 - 01:30 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	ATI-1777	None	None	Phase 2b Data Readout Q2 2026
ADAP	Adaptimmune Therapeutics plc	200M	800K	2.01	3.5% - 9%	\$0.85 - 01:30 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare	Biotechnology	Aficanten	None	Aficanten Fast Track 2022	Phase 3 Data Readout Q4 2026
ADPT	Adaptive Biotechnologies Corp.	650M	700K	1.87	2.8% - 7.5%	\$3.60 - 01:30 PM EDT 06/10/2025	No	Stable	Commercial	Healthcare	Biotechnology	clonoSEQ	clonoSEQ Sep 2018	None	New Indication Data Q3 2025
ADMA	ADMA Biologics Inc.	1.2B	2.5M	1.45	2% - 6%	\$10.80 - 01:30 PM EDT 06/10/2025	Yes - Large Purchase	Increase	Commercial	Healthcare	Biotechnology	ASCENIV BVIGAM	ASCENIV Apr 2019 BVIGAM Oct 2019	None	None
AGEN	Agenus Inc.	250M	1.8M	1.98	3.5% - 9%	\$0.65 - 01:30 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare	Biotechnology	Botenslimab	None	None	Phase 2 Data Readout Q1 2026
AGIO	Agiros Pharmaceuticals Inc.	2.4B	600K	1.76	2.5% - 7%	\$43.50 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase	Stable	Commercial	Healthcare	Biotechnology	PYRUKYND	PYRUKYND Feb 2022	PYRUKYND Fast Track 2020	Phase 3 Data Readout Q2 2026
ALDX	Aldaya Therapeutics Inc.	350M	400K	1.92	3% - 8%	\$3.90 - 01:30 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	Reproxalap	None	Reproxalap Fast Track 2019	Phase 3 Data Readout Q4 2025
ALEC	Alector Inc.	450M	500K	1.67	2.8% - 7.5%	\$5.10 - 01:30 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare	Biotechnology	Latozinemab	None	Latozinemab Fast Track 2023	Phase 3 Data Readout Q3 2026
ALLO	Allogene Therapeutics Inc.	400M	900K	1.88	3.2% - 8.5%	\$2.70 - 01:30 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	Cema-cel	None	Cema-cel Fast Track 2022	Phase 2 Data Readout Q3 2026
ALNY	Alnylam Pharmaceuticals Inc.	19.5B	700K	1.23	2% - 5.5%	\$152.30 - 01:30 PM EDT 06/10/2025	Yes - Large Purchase	Increase	Commercial	Healthcare	Biotechnology	AMVUTTRA Givlaari Oxumo	AMVUTTRA Jun 2022 Givlaari Nov 2019 Oxumo Nov 2020	AMVUTTRA Fast Track 2021	Phase 3 Data Readout Utrivrian Q1 2026
AMRX	Amneal Pharmaceuticals Inc.	2.1B	1.3M	1.45	2% - 6%	\$6.95 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase	Stable	Commercial	Healthcare	Pharmaceuticals	Generic Drugs	N/A	N/A	N/A
AKRO	Akero Therapeutics Inc.	1.8B	800K	1.78	2.8% - 7.5%	\$24.50 - 01:30 PM EDT 06/10/2025	No	Increase	Clinical	Healthcare	Biotechnology	EFX	None	EPX Fast Track 2020	Phase 3 Data Readout Q4 2026
ANAB	AnaptgBio Inc.	650M	300K	1.65	2.5% - 7%	\$24.80 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase	Stable	Clinical	Healthcare	Biotechnology	Roslimab	None	None	Phase 2 Data Readout Q2 2026
ANVS	Annovis Bio Inc.	120M	1.2M	2.10	4% - 10%	\$6.50 - 01:30 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare	Biotechnology	Bur坦etap	None	Bur坦etap Fast Track 2023	Phase 3 Data Readout Q3 2026
APLS	Apellis Pharmaceuticals Inc.	4.8B	1.1M	1.54	2% - 6%	\$40.20 - 01:30 PM EDT 06/10/2025	Yes - Large Purchase	Increase	Commercial	Healthcare	Biotechnology	SYOVRE Empavell	SYOVRE Feb 2023 Empavell May 2021	SYOVRE Fast Track 2022	Phase 3 Data Readout Q1 2026
ARCT	Arbutus Biopharma Corp.	450M	600K	1.92	3% - 8%	\$3.10 - 01:30 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	ARCT-810	None	None	Phase 2 Data Readout Q4 2026
ARXY	ArdeyX Inc.	750M	2.8M	1.87	3.2% - 8.5%	\$6.35 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Commercial	Healthcare	Biotechnology	IBSRELA XPHOZAH	IBSRELA Apr 2022 XPHOZAH Oct 2023	IBSRELA Fast Track 2021	Phase 4 Data Readout Q3 2026
ARGX	argenx SE	12.5B	300K	1.12	1.8% - 5%	\$445.50 - 01:30 PM EDT 06/10/2025	Yes - Large Purchase	Increase	Commercial	Healthcare	Biotechnology	VYVGART	VYVGART Jun 2021	VYVGART Fast Track 2020	Phase 3 Data Readout Efgartigimod Q2 2026
ARMP	Armata Pharmaceuticals Inc.	75M	50K	1.92	3.5% - 9%	\$2.80 - 01:30 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	AP-PA02	None	None	None
ARTO	Arctus Biotherapeutics Inc.	650M	1.6M	1.78	2.8% - 7.5%	\$8.90 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Commercial	Healthcare	Biotechnology	ZORRYE	ZORRYE Jul 2022	None	Phase 4 Data Readout Q2 2026
ARVN	Arvinas Inc.	1.4B	700K	1.87	2.5% - 7%	\$26.50 - 01:30 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	ARV-110	None	None	Phase 2 Data Readout Q4 2025
ASMB	Assembly Biosciences Inc.	90M	30K	1.65	3% - 8%	\$14.20 - 01:30 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare	Biotechnology	ABI-4334	None	None	Phase 1b Data Readout Q3 2026
ASND	Ascendis Pharma A/S	4.8B	300K	1.45	2% - 6%	\$135.40 - 01:30 PM EDT 06/10/2025	Yes - Large Purchase	Increase	Commercial	Healthcare	Biotechnology	SKYTROFA YORVIPATH	SKYTROFA Aug 2021 YORVIPATH Aug 2024	SKYTROFA Fast Track 2020	Phase 3 Data Readout TransCon CNP Q1 2026
ATHA	Athira Pharma Inc.	100M	200K	1.92	3.5% - 9%	\$2.60 - 01:30 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare	Biotechnology	Fosgorimetron	None	None	Phase 2/3 Data Readout Q4 2025
ATXS	Astria Therapeutics Inc.	350M	400K	1.76	2.8% - 7.5%	\$9.80 - 01:30 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	STAR-0215	None	STAR-0215 Fast Track 2023	Phase 1b Data Readout Q2 2026
ATYR	aTyR Pharma Inc.	150M	250K	1.87	3% - 8%	\$1.95 - 01:30 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare	Biotechnology	ATYR1923	None	None	Phase 2 Data Readout Q3 2026
AURA	Aura Biosciences Inc.	300M	200K	1.65	2.5% - 7%	\$7.50 - 01:30 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	Bel-sar	None	Bel-sar Fast Track 2022	Phase 3 Data Readout Q4 2026
AURP	Aurinia Pharmaceuticals Inc.	900M	1.4M	1.54	2% - 6%	\$6.20 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Commercial	Healthcare	Biotechnology	LUPKYNIS	LUPKYNIS Jan 2021	Phase 4 Data Readout Q3 2026	Phase 3 Data Readout Q3 2026
AVIR	Attea Pharmaceuticals Inc.	350M	600K	1.78	2.8% - 7.5%	\$4.10 - 01:30 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	Bemlfozabuvir	None	None	Phase 3 Data Readout Q2 2026
AVXL	Anavex Life Sciences Corp.	450M	1.1M	1.92	3.2% - 8.5%	\$5.40 - 01:30 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare	Biotechnology	Biacarnesine	None	Biacarnesine Fast Track 2021	Phase 3 Data Readout Q1 2026
AXSM	Axsome Therapeutics Inc.	3.8B	800K	1.65	2% - 6%	\$85.60 - 01:30 PM EDT 06/10/2025	Yes - Large Purchase	Increase	Commercial	Healthcare	Biotechnology	AUVELITY SUNOSI	AUVELITY Aug 2022 SUNOSI Jun 2019	AUVELITY Fast Track 2021	Phase 3 Data Readout AXS-12 Q4 2025
BBIO	BridgeBio Pharma Inc.	2.9B	1.3M	1.76	2.5% - 7%	\$26.80 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Clinical	Healthcare	Biotechnology	Acoramidis	None	Acoramidis Fast Track 2023	Phase 3 Data Readout Q1 2026
BCAX	Bicara Therapeutics Inc.	700M	400K	1.54	2.8% - 7.5%	\$18.50 - 01:30 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	Ficzanib	None	None	Phase 2 Data Readout Q3 2026
BCRX	BioCryst Pharmaceuticals Inc.	1.5B	2.5M	1.87	2.5% - 7%	\$7.90 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Commercial	Healthcare	Biotechnology	ORLADEYO	ORLADEYO Dec 2020	ORLADEYO Fast Track 2020	Phase 3 Data Readout Avoralstat Q2 2026
BEAM	Beam Therapeutics Inc.	1.7B	900K	1.92	3% - 8%	\$24.30 - 01:30 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	BEAM-101	None	BEAM-101 Fast Track 2022	Phase 1 Data Readout Q4 2025
BIIB	Biogen Inc.	27.5B	1.2M	1.23	1.8% - 5%	\$190.20 - 01:30 PM EDT 06/10/2025	Yes - Large Purchase	Stable	Commercial	Healthcare	Biotechnology	SPINRAZA LEQEMBI	SPINRAZA Dec 2016 LEQEMBI Jan 2023	LEQEMBI Fast Track 2022	Phase 3 Data Readout Q1 2026
BLRX	BioLineRx Ltd.	150M	500K	1.65	3.2% - 8.5%	\$9.70 - 01:30 PM EDT 06/10/2025	No	Decrease	Commercial	Healthcare	Biotechnology	APHEXDA	APHEXDA Sep 2023	APHEXDA Fast Track 2022	Commercial Expansion Q4 2025
BMEA	Biomesa Fusion Inc.	250M	600K	2.01	3.5% - 9%	\$6.80 - 01:30 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	BMF-219	None	None	Phase 2 Data Readout Q3 2026
BMNR	BioMarin Pharmaceutical Inc.	14.5B	1.4M	1.34	1.8% - 5%	\$78.50 - 01:30 PM EDT 06/10/2025	Yes - Large Purchase	Increase	Commercial	Healthcare	Biotechnology	VOXZOGO ROCTAVIAN	VOXZOGO Nov 2021 ROCTAVIAN Jun 2023	VOXZOGO Fast Track 2020	Phase 3 Data Readout BMN 307 Q2 2026
BNXT	BioNTech SE	22.8B	700K	1.45	2% - 6%	\$95.20 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase	Stable	Commercial	Healthcare	Biotechnology	COMIRNATY	COMIRNATY Aug 2021	COMIRNATY Fast Track 2020	Phase 3 Data Readout BNT324 Q1 2026
BPMC	Blueprint Medicines Corp.	3.5B	500K	1.54	2.5% - 7%	\$95.80 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Commercial	Healthcare	Biotechnology	AVAKIT GAVRETO	AVAKIT Jun 2020 GAVRETO Sep 2020	AVAKIT Fast Track 2020	Phase 3 Data Readout BLU-222 Q4 2025
BTAI	BioXcel Therapeutics Inc.	150M	700K	2.10	3.5% - 9%	\$1.80 - 01:30 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare	Biotechnology	BXCL501	IGALMI Apr 2022	IGALMI Fast Track 2021	Phase 3 Data Readout BXCL501 Q3 2026
CADL	Candel Therapeutics Inc.	120M	1.2M	2.10	3.5% - 9%	\$5.80 - 01:30 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	CAN-2409	None	CAN-2409 Fast Track 2021	Phase 3 Data Readout Q4 2025
CANF	Can-Fite BioPharma Ltd.	50M	150K	1.87	3% - 8%	\$2.10 - 01:30 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare	Biotechnology	Namodenoson	None	None	Phase 3 Data Readout Q3 2026
CAPR	Capricor Therapeutics Inc.	150M	400K	1.92	3.2% - 8.5%	\$5.40 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase	Stable	Clinical	Healthcare	Biotechnology	Deramiscoel	None	Deramiscoel Fast Track 2023	Phase 3 Data Readout Q2 2026
CELC	Celcuty Inc.	350M	200K	1.76	2.8% - 7.5%	\$16.80 - 01:30 PM EDT 06/10/2025	No	Increase	Clinical	Healthcare	Biotechnology	Gedatolisib	None	None	Phase 3 Data Readout Q4 2026
CELU	Celularity Inc.	80M	300K	1.98	3.5% - 9%	\$2.90 - 01:30 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare	Biotechnology	CYNK-001	None	None	Phase 1 Data Readout Q3 2026
CELZ	Creative Medical Technology Holdings Inc.	30M	50K	2.01	4% - 10%	\$3.50 - 01:30 PM EDT 06/10/2025	No	Stable	Pre-Clinical	Healthcare	Biotechnology	CELZ-201	None	None	None
CLDX	Celldex Therapeutics Inc.	1.8B	600K	1.65	2.5% - 7%	\$38.50 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Clinical	Healthcare	Biotechnology	Barzolvolimab	None	Barzolvolimab Fast Track 2023	Phase 2 Data Readout Q1 2026
CGEM	Cullinan Oncology Inc.	600M	400K	1.54	2.8% - 7.5%	\$17.20 - 01:30 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	Zpalertinib	None	None	Phase 3 Data Readout Q4 2026
CGON	CG Oncology Inc.	1.2B	500K	1.45	2.5% - 7%	\$32.40 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Clinical	Healthcare	Biotechnology	Cretostimogene	None	Cretostimogene Fast Track 2023	Phase 3 Data Readout Q2 2026
CGTX	Cognition Therapeutics Inc.	90M	200K	1.92	3.2% - 8.5%	\$2.30 - 01:30 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare	Biotechnology	CT1812	None	None	Phase 2 Data Readout Q3 2026
CHRS	Chorus BioSciences Inc.	150M	1.5M	2.01	3.5% - 9%	\$1.60 - 01:30 PM EDT 06/10/2025	No	Stable	Commercial	Healthcare	Biotechnology	UDENYCA	UDENYCA Nov 2018	UDENYCA Fast Track 2018	Commercial Expansion Q4 2025
CKPT	Checkpoint Therapeutics Inc.	80M	600K	1.87	3% - 8%	\$2.20 - 01:30 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare	Biotechnology	Cosbelimab	None	Cosbelimab Fast Track 2022	Phase 3 Data Readout Q1 2026
CLSD	Clearead Biomedical Inc.	90M	400K	1.92	3.2% - 8.5%	\$1.20 - 01:30 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	CLS-AX	None	None	Phase 2b Data Readout Q4 2025
CLLS	Cellectis S.A.	200M	150K	1.76	2.8% - 7.5%	\$2.50 - 01:30 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare	Biotechnology	UCART123	None	None	Phase 1 Data Readout Q3 2026
CMXP	Compass Therapeutics Inc.	120M	300K	1.65	3% - 8%	\$1.40 - 01:30 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	CTX-009	None	None	Phase 2 Data Readout Q2 2026
CNTA	Centessa Pharmaceuticals plc	800M	400K	1.54	2.5% - 7%	\$9.80 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Clinical	Healthcare	Biotechnology	SerpinPC	None	SerpinPC Fast Track 2023	Phase 2b Data Readout Q4 2025
COGT	Cogent Biosciences Inc.	650M	700K	1.87	2.8% - 7.5%	\$8.90 - 01:30 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	Bezuciclastinib	None	None	Phase 3 Data Readout Q3 2026
COVA	Coya Therapeutics Inc.	200M	150K	1.92	3.2% - 8.5%	\$7.20 - 01:30 PM EDT 06/10/2025	No	Increase	Clinical	Healthcare	Biotechnology	COVA-301	None	None	Phase 2 Data Readout Q4 2026
CORT	Corcept Therapeutics Inc.	3.2B	800K	1.45	2% - 6%	\$34.50 - 01:30 PM EDT 06/10/2025	Yes - Large Purchase	Increase	Commercial	Healthcare	Biotechnology	KORLYM	KORLYM Feb 2012	None	Phase 3 Data Readout Relacoriant Q1 2026
CPRX	Catalyst Pharmaceuticals Inc.	2.6B	1.2M	1.34	2% - 6%	\$25.90 - 01:30 PM EDT 06/10/2025	Yes - Large Purchase	Increase	Commercial	Healthcare	Biotechnology	FIRDAPSE AGAMREE	FIRDAPSE Nov 2018 AGAMREE Oct 2023	FIRDAPSE Fast Track 2018	Phase 4 Data Readout Q3 2026
CRBP	Corbus Pharmaceuticals Holdings Inc.	450M	1.1M	1.76	2.8% - 7.5%	\$9.80 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Clinical	Healthcare	Biotechnology	CRB-701	None	None	Phase 2 Data Readout Q4 2025
CRIS	Curis Inc.	80M	200K	1.92	3.2% - 8.5%	\$4.50 - 01:30 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare	Biotechnology</				

KOD	Kodak Sciences Inc.	200M	600K	2.01	3.5% - 9%	\$3.20 - 01:55 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare	Biotechnology	Tarocimab	None	None	Phase 3 Data Readout Q4 2025
KROS	Keros Therapeutics Inc.	1.8B	400K	1.54	2.5% - 7%	\$48.50 - 01:55 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Clinical	Healthcare	Biotechnology	Elitrocept	None	None	Phase 2 Data Readout Q1 2026
KURA	Kura Oncology Inc.	1.2B	600K	1.87	2.8% - 7.5%	\$20.80 - 01:55 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	Ziftomenib	None	Ziftomenib Fast Track 2023	Phase 2 Data Readout Q4 2025
KTTA	Krystal Biotech Inc.	5.2B	300K	1.45	2% - 6%	\$180.50 - 01:55 PM EDT 06/10/2025	Yes - Large Purchase	Increase	Commercial	Healthcare	Biotechnology	Vyjuvek	Vyjuvek May 2023	Vyjuvek Fast Track 2022	Phase 3 Data Readout KB707 Q2 2026
KYMR	Kymira Therapeutics Inc.	2.5B	500K	1.65	2.5% - 7%	\$38.20 - 01:55 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Clinical	Healthcare	Biotechnology	KT-474	None	None	Phase 2 Data Readout Q1 2026
LEGN	Legend Biotech Corporation	8.5B	1.1M	1.54	2% - 6%	\$46.50 - 01:55 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Commercial	Healthcare	Biotechnology	Carvykti	Carvykti Feb 2022	Carvykti Fast Track 2021	Phase 3 Data Readout LB-100 Q3 2026
LENZ	Lenz Therapeutics Inc.	350M	200K	1.92	3.2% - 8.5%	\$15.80 - 01:55 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	LNZ100	None	LNZ100 Fast Track 2023	Phase 3 Data Readout Q4 2025
LGND	Ligand Pharmaceuticals Inc.	1.8B	300K	1.45	2% - 6%	\$98.50 - 01:55 PM EDT 06/10/2025	Yes - Moderate Purchase	Stable	Commercial	Healthcare	Biotechnology	Captisol Technology	Multiple Captisol-based drugs	None	Commercial Expansion Q4 2025
LQDA	Liquidia Corporation	650M	700K	1.87	2.8% - 7.5%	\$12.20 - 01:55 PM EDT 06/10/2025	No	Increase	Commercial	Healthcare	Biotechnology	Yutrepia	Yutrepia Nov 2024	Yutrepia Fast Track 2022	Commercial Expansion Q4 2025
LRMR	Larimar Therapeutics Inc.	300M	400K	1.92	3.2% - 8.5%	\$8.50 - 01:55 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	Nomiabofusp	None	Nomiabofusp Fast Track 2023	Phase 2 Data Readout Q2 2026
LXRX	Lexicon Pharmaceuticals Inc.	350M	1.2M	2.01	3.5% - 9%	\$2.10 - 01:55 PM EDT 06/10/2025	No	Decrease	Commercial	Healthcare	Biotechnology	Impella	Impella May 2023	Impella Fast Track 2022	Phase 3 Data Readout LX9211 Q3 2026
LYEL	Lyell Immunopharma Inc.	200M	500K	1.76	3% - 8%	\$2.80 - 01:55 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare	Biotechnology	LYL797	None	LYL797 Fast Track 2023	Phase 1 Data Readout Q4 2025
MDGL	Madrigal Pharmaceuticals Inc.	5.5B	600K	1.65	2.5% - 7%	\$280.50 - 01:55 PM EDT 06/10/2025	Yes - Large Purchase	Increase	Commercial	Healthcare	Biotechnology	Rezdiffra	Rezdiffra Mar 2024	Rezdiffra Fast Track 2022	Commercial Expansion Q4 2025
MESO	Mesoblast Limited	1.2B	200K	1.87	2.8% - 7.5%	\$7.50 - 01:55 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	Remestemcel-L	None	Remestemcel-L Fast Track 2019	Phase 3 Data Readout Q2 2026
MGXN	MacroGenics Inc.	200M	1.1M	2.01	3.5% - 9%	\$4.50 - 01:55 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare	Biotechnology	Vobramitamab	None	None	Phase 2 Data Readout Q3 2026
MGTX	MeiraGTx Holdings plc	350M	300K	1.76	2.8% - 7.5%	\$5.20 - 01:55 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	AAV-GAD	None	None	Phase 2 Data Readout Q4 2025
MGX	Metagenomi Inc.	150M	400K	1.92	3.2% - 8.5%	\$4.80 - 01:55 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare	Biotechnology	MGX-001	None	None	Phase 1 Data Readout Q3 2026
MIRM	Mirum Pharmaceuticals Inc.	1.5B	500K	1.65	2.5% - 7%	\$38.20 - 01:55 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Commercial	Healthcare	Biotechnology	Livmarli	Livmarli Nov 2020	Livmarli Fast Track 2020	Phase 3 Data Readout Vxilixbat Q1 2026
MLYS	Minerals Therapeutics Inc.	450M	300K	1.87	2.8% - 7.5%	\$13.50 - 01:55 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	Lorundrostat	None	None	Phase 3 Data Readout Q4 2025
MNKD	ManKind Corporation	1.4B	2.1M	1.76	2.8% - 7.5%	\$5.80 - 01:55 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Commercial	Healthcare	Biotechnology	Afrezza	Afrezza Jun 2014	Afrezza Fast Track 2013	Commercial Expansion Q4 2025
MNMD	Mind Medicine (MindMed) Inc.	600M	1.5M	2.01	3.5% - 9%	\$8.50 - 01:55 PM EDT 06/10/2025	No	Increase	Clinical	Healthcare	Biotechnology	MM-120	None	MM-120 Fast Track 2022	Phase 3 Data Readout Q3 2026
MREO	Mereo BioPharma Group plc	600M	1.2M	1.76	2.8% - 7.5%	\$4.50 - 01:58 PM EDT 06/10/2025	Yes - Moderate Purchase	Stable	Clinical	Healthcare	Biotechnology	Setrusumab	None	Setrusumab Fast Track 2022	Phase 3 Data Readout Q3 2025
MRRS	Marinus Pharmaceuticals Inc.	80M	600K	2.01	3.5% - 9%	\$1.40 - 01:58 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare	Biotechnology	Ganaxolone	Zalzmy Mar 2022	Ganaxolone Fast Track 2021	Phase 3 Data Readout Q2 2026
MRSN	Mersana Therapeutics Inc.	150M	1.1M	1.92	3.2% - 8.5%	\$2.10 - 01:58 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	XMT-1660	None	None	Phase 1 Data Readout Q4 2025
MRSU	Merus N.V.	2.5B	500K	1.65	2.5% - 7%	\$55.80 - 01:58 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Clinical	Healthcare	Biotechnology	Zenocutuzumab	None	Zenocutuzumab Fast Track 2021	Phase 2 Data Readout Q1 2026
MTEM	Molecular Templates Inc.	80M	300K	2.10	3.5% - 9%	\$1.20 - 01:58 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare	Biotechnology	MT-6402	None	None	Phase 1 Data Readout Q3 2026
NAAMS	NewAmsterdam Pharma Company N.V.	1.8B	400K	1.54	2.5% - 7%	\$20.50 - 01:58 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Clinical	Healthcare	Biotechnology	Oicetrapib	None	None	Phase 3 Data Readout Q4 2025
NAUT	Nautilus Biotechnology Inc.	200M	200K	1.76	2.8% - 7.5%	\$2.80 - 01:58 PM EDT 06/10/2025	No	Stable	Pre-Clinical	Healthcare	Biotechnology	N/A	None	None	None
NBTX	Nanobiotix S.A.	350M	150K	1.87	3% - 8%	\$6.50 - 01:58 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare	Biotechnology	NBTXR3	None	NBTXR3 Fast Track 2022	Phase 3 Data Readout Q2 2026
NRIX	Nurix Therapeutics Inc.	1.2B	600K	1.92	3.2% - 8.5%	\$20.80 - 01:58 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Clinical	Healthcare	Biotechnology	NX-5948	None	None	Phase 1 Data Readout Q4 2025
NTLA	Intellia Therapeutics Inc.	2.1B	1.4M	1.76	2.8% - 7.5%	\$22.50 - 01:58 PM EDT 06/10/2025	Yes - Moderate Purchase	Stable	Clinical	Healthcare	Biotechnology	NTLA-2001	None	NTLA-2001 Fast Track 2022	Phase 3 Data Readout Q1 2026
NUTV	Nuvation Bio Inc.	650M	500K	1.65	2.5% - 7%	\$3.20 - 01:58 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	Talazoparib	None	None	Phase 2 Data Readout Q4 2025
NUVL	Nuvent Inc.	5.2B	400K	1.54	2% - 6%	\$80.50 - 01:58 PM EDT 06/10/2025	Yes - Large Purchase	Increase	Clinical	Healthcare	Biotechnology	NVL-520	None	None	Phase 2 Data Readout Q2 2026
NVO	Novo Nordisk A/S	580B	1.8M	1.23	1.8% - 5%	\$130.20 - 01:58 PM EDT 06/10/2025	Yes - Large Purchase	Stable	Commercial	Healthcare	Biotechnology	Nzempic Wegovy Rybelsus	Ozempic Mar 2017 Wegovy Jun 2021 Rybelsus Sep 2019	Ozempic Fast Track 2016	Phase 3 Data Readout CagriSema Q1 2026
OABI	OmniAb Inc.	600M	300K	1.45	2% - 6%	\$5.20 - 01:58 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	O/A	None	None	None
OCUL	Ocular Therapeutix Inc.	650M	700K	1.87	2.8% - 7.5%	\$8.50 - 01:58 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Commercial	Healthcare	Biotechnology	Dextenza	Dextenza Dec 2016	Dextenza Fast Track 2018	Phase 3 Data Readout APAXLI Q4 2025
OLMA	Olema Pharmaceuticals Inc.	600M	500K	1.92	3.2% - 8.5%	\$12.80 - 01:58 PM EDT 06/10/2025	No	Increase	Clinical	Healthcare	Biotechnology	Palaestrand	None	None	Phase 3 Data Readout Q1 2026
OMER	Omeros Corporation	200M	600K	2.01	3.5% - 9%	\$3.50 - 01:58 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare	Biotechnology	Narsoplimab	None	Narsoplimab Fast Track 2020	Phase 3 Data Readout Q4 2025
ORIC	ORIC Pharmaceuticals Inc.	350M	400K	1.76	2.8% - 7.5%	\$8.50 - 01:58 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	ORIC-114	None	None	Phase 1 Data Readout Q4 2025
OSCR	Oscar Health Inc.	4.8B	1.5M	1.54	2% - 6%	\$20.50 - 01:58 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Commercial	Healthcare	Health Insurance	N/A	N/A	N/A	Commercial Expansion Q4 2025
OSMT	Osimetric Pharmaceuticals plc	150M	200K	1.87	3% - 8%	\$2.20 - 01:58 PM EDT 06/10/2025	No	Decrease	Commercial	Healthcare	Biotechnology	Upnreeq	Upnreeq Jul 2020	Upnreeq Fast Track 2020	Commercial Expansion Q4 2025
PBYI	Puma Biotechnology Inc.	200M	400K	2.01	3.5% - 9%	\$3.80 - 01:58 PM EDT 06/10/2025	No	Stable	Commercial	Healthcare	Biotechnology	Nerlynx	Nerlynx Jul 2017	Nerlynx Fast Track 2016	Phase 2 Data Readout Q3 2026
PCVX	Pocyte Inc.	4.5B	600K	1.65	2.5% - 7%	\$75.20 - 01:58 PM EDT 06/10/2025	Yes - Large Purchase	Increase	Clinical	Healthcare	Biotechnology	VAX-24	None	VAX-24 Fast Track 2023	Phase 3 Data Readout Q3 2026
PDSB	PDS Biotechnology Corporation	200M	700K	1.92	3.2% - 8.5%	\$3.50 - 01:58 PM EDT 06/10/2025	No	Increase	Clinical	Healthcare	Biotechnology	PDS0101	None	PDS0101 Fast Track 2022	Phase 2 Data Readout Q3 2025
PGEN	Precigen Inc.	150M	1.2M	2.01	3.5% - 9%	\$1.40 - 02:01 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare	Biotechnology	PRGN-2012	None	PRGN-2012 Fast Track 2022	Phase 2 Data Readout Q2 2025
PHAR	Pharming Group N.V.	350M	200K	1.76	2.8% - 7.5%	\$8.50 - 02:01 PM EDT 06/10/2025	No	Stable	Commercial	Healthcare	Biotechnology	Lenilisib	Joenja Apr 2023	Joenja Fast Track 2022	Commercial Expansion Q4 2025
PHAT	Phathom Pharmaceuticals Inc.	600M	500K	1.87	3% - 8%	\$12.80 - 02:01 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Commercial	Healthcare	Biotechnology	Voquezna	Voquezna Aug 2024	Voquezna Fast Track 2023	Commercial Expansion Q4 2025
PHVS	Pharvaris N.V.	450M	300K	1.65	2.5% - 7%	\$18.50 - 02:01 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	Deuciricbant	None	Deuciricbant Fast Track 2023	Phase 3 Data Readout Q1 2026
PLRX	Plant Therapeutics Inc.	650M	400K	1.92	3.2% - 8.5%	\$12.20 - 02:01 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Clinical	Healthcare	Biotechnology	Bexotegrast	None	Bexotegrast Fast Track 2022	Phase 2b Data Readout Q4 2025
PLUR	Pluristem Therapeutics Inc.	80M	200K	2.10	3.5% - 9%	\$5.50 - 02:01 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare	Biotechnology	PLX-PAD	None	None	Phase 3 Data Readout Q3 2026
PRME	Prime Medicine Inc.	350M	500K	1.76	2.8% - 7.5%	\$5.80 - 02:01 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	PM359	None	None	Phase 1 Data Readout Q4 2025
PRTA	Prothena Corporation plc	1.2B	600K	1.65	2.5% - 7%	\$22.50 - 02:01 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Clinical	Healthcare	Biotechnology	PRX012	None	None	Phase 2 Data Readout Q2 2026
PTCT	PTC Therapeutics Inc.	2.5B	700K	1.54	2% - 6%	\$35.80 - 02:01 PM EDT 06/10/2025	Yes - Moderate Purchase	Stable	Commercial	Healthcare	Biotechnology	Emflaza Upstaza	Emflaza Apr 2017 Upstaza (EU Approved 2022)	Emflaza Fast Track 2016	Phase 3 Data Readout Vatiquinone Q1 2026
PTGX	Protagonist Therapeutics Inc.	1.8B	500K	1.87	2.8% - 7.5%	\$35.20 - 02:01 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Clinical	Healthcare	Biotechnology	Rusterfide	None	Rusterfide Fast Track 2023	Phase 3 Data Readout Q3 2025
QURE	uniQure N.V.	350M	600K	1.92	3.2% - 8.5%	\$5.50 - 02:01 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare	Biotechnology	AMT-130	None	AMT-130 Fast Track 2021	Phase 1/2 Data Readout Q3 2026
RARE	Ultragenyx Pharmaceutical Inc.	4.2B	700K	1.65	2.5% - 7%	\$48.50 - 02:01 PM EDT 06/10/2025	Yes - Large Purchase	Increase	Commercial	Healthcare	Biotechnology	Mapepivl Crysvita Dojohi	Mapepivl Nov 2017 Crysvita Apr 2018 Dojohi Jun 2020	Mapepivl Fast Track 2017	Phase 3 Data Readout LX701 Q3 2026
RCKT	Rocket Pharmaceuticals Inc.	1.5B	600K	1.76	2.8% - 7.5%	\$20.80 - 02:01 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Clinical	Healthcare	Biotechnology	RP-L201	None	RP-L201 Fast Track 2021	Phase 2 Data Readout Q1 2026
RCUS	Arcus Biosciences Inc.	1.2B	800K	1.87	3% - 8%	\$15.80 - 02:01 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	Etrundenant	None	None	Phase 2 Data Readout Q4 2025
REGN	Regeneron Pharmaceuticals Inc.	115B	500K	1.23	1.8% - 5%	\$1050.20 - 02:01 PM EDT 06/10/2025	Yes - Large Purchase	Increase	Commercial	Healthcare	Biotechnology	Eylea Dupixent	Eylea Aug 2011 Dupixent Mar 2017	Dupixent Fast Track 2016	Phase 3 Data Readout Odnexntamab Q1 2026
REPL	Replimune Group Inc.	350M	700K	1.92	3.2% - 8.5%	\$8.50 - 02:01 PM EDT 06/10/2025	No	Increase	Clinical	Healthcare	Biotechnology	RP1	None	None	Phase 2 Data Readout Q4 2025
RGNX	REGENXBIO Inc.	600M	600K	1.76	2.8% - 7.5%	\$12.80 - 02:01 PM EDT 06/10/2025	Yes - Moderate Purchase	Stable	Clinical	Healthcare	Biotechnology	RGX-121	None	RGX-121 Fast Track 2021	Phase 3 Data Readout Q2 2026
RIGL	Rigel Pharmaceuticals Inc.	200M	1.1M	2.01	3.5% - 9%	\$1.20 - 02:01 PM EDT 06/10/2025	No	Decrease	Commercial	Healthcare	Biotechnology	Rezidhia	Rezidhia Dec 2022	Rezidhia Fast Track 2022	Commercial Expansion Q4 2025
RLAY	Relay Therapeutics Inc.	650M	700K	1.87	3% - 8%	\$8.50 - 02:01 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	RLY-2608	None	None	Phase 1 Data Readout Q4 2025
RNA	Ardely Biosciences Inc.	2.5B	600K	1.76	2.8% - 7.5%	\$38.50 - 02:01 PM EDT 06/10/2025	Yes - Large Purchase	Increase	Clinical	Healthcare	Biotechnology	AOC 1001	None	AOC 1001 Fast Track 2022	Phase 2 Data Readout Q1 2026
RRPX	Royalty Pharma plc	12.5B	2.1M	1.34	1.8% - 5%	\$28.50 - 02:01 PM EDT 06/10/2025	Yes - Moderate Purchase	Stable	Commercial	Healthcare	Biotechnology	N/A	Multiple Royalty Agreements	None	Commercial Expansion Q4 2025
RVMD	Revolution Medicines Inc.	3.5B	700K	1.65	2.5% - 7%	\$45.20 - 02:01 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Clinical	Healthcare	Biotechnology	RMC-6236	None	None	Phase 1 Data Readout Q4 2025
RXRK	Recursion Pharmaceuticals Inc.	650M	1.5M	1.92	3.2% - 8.5%	\$8.80 - 02:01 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare	Biotechnology	REC-994	None	None	Phase 2 Data Readout Q3 2026
RYTM	Rhythm Pharmaceuticals Inc.	2.8B	500K	1.54	2% - 6%	\$48.50 - 02:01 PM EDT 06/10/2025	Yes - Large Purchase	Increase	Commercial	Healthcare	Biotechnology	Imcivree	Imcivree Nov 2020	Imcivree Fast Track 2020	Phase 3 Data Readout LB5640 Q2 2026
RZLT	Rezolute Inc.	200M	300K	2.01	3.5% - 9%	\$3.80 - 02:01 PM EDT 06/10/2025	No	Increase	Clinical	Healthcare	Biotechnology	RZ358	None	None	Phase 2 Data Readout Q4 2025
SAGE	Sage Therapeutics Inc.	650M	800K	1.87	2.8% - 7.5%	\$10.80 - 02:15 PM EDT 06/10/2025	Yes - Moderate Purchase	Stable	Commercial	Healthcare	Biotechnology	Zuranolone	Zurlesso Mar 2019 Zurzuvae Aug 2023	Zuranolone Fast Track 2022	Phase 3 Data Readout SAGE-324 Q2 2026
SANA	Sana Biotechnology Inc.	1.5B	700K	1.92	3.2% - 8.5%	\$6.80 - 02:15 PM EDT 06/10/2025	No	Increase	Clinical	Healthcare	Biotechnology	SC291	None	None	Phase 1 Data Readout Q4 2025
SGMO	Sangamo Therapeutics Inc.	200M	1.5M	2.01	3.5% - 9%	\$9.80 - 02:15 PM EDT 06/10/2025	No	10% Decrease	Clinical	Healthcare	Biotechnology	SB-525	None	None	Phase 3 Data Readout Q4 2025
SLDB															

Partners	Space	Competitors	Cash_Runway	Last_Earnings_Date	Last_Earnings_Result	Next_Earnings_Date	Rating	SA_Rating	Country
Lilly (LLY) Pfizer (PFE)	Antibody Discovery	Amgen (AMGN) Regeneron (REGN)	24 months	May 7 2025	EPS -0.14 -6% Miss Revenue 9.8M -10% Miss	Aug 5 2025 (est.)	6 (B)	HOLD	Canada
None	Gene Therapy	Krystal Biotech (KRYS)	18 months	May 8 2025	EPS -0.45 -8% Miss Revenue 0.3M -20% Miss	Aug 4 2025 (est.)	5 (B-)	HOLD	USA
AstraZeneca (AZN) Merck (MRK)	AI-Driven Drug Discovery	Schrodinger (SDGR) Recursion (RXRX)	20 months	May 8 2025	EPS -0.22 -5% Miss Revenue 1.8M +10% Beat	Aug 6 2025 (est.)	7 (B+)	BUY	USA
None	HBV Therapy	Gilead (GILD) Moderna (MRNA)	15 months	May 2 2025	EPS -0.12 -10% Miss Revenue 1.5M -15% Miss	Jul 31 2025 (est.)	6 (B)	HOLD	Canada
None	CNS Disorders	Eisai (ESALY) Biogen (BIIB)	30 months	May 8 2025	EPS 0.10 +15% Beat Revenue 205.8M +8% Beat	Aug 6 2025 (est.)	8 (A-)	BUY	USA
Regeneron (REGN)	Cell Therapy	Alogene (ALLO) Fate Therapeutics (FATE)	12 months	May 7 2025	EPS -0.36 -12% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	5 (B-)	SELL	USA
Kite/Gilead (GILD)	Cell Therapy	Alogene (ALLO) Caribou (CRBU)	24 months	May 9 2025	EPS -0.50 -5% Miss Revenue 21.3M +12% Beat	Aug 7 2025 (est.)	7 (B+)	BUY	USA
None	Dermatology	Incyte (INCY) Dermavant	12 months	May 7 2025	EPS -0.15 -10% Miss Revenue 2.4M -8% Miss	Aug 5 2025 (est.)	5 (B-)	HOLD	USA
GSK (GSK)	T-Cell Therapy	Immunocore (IMCR) TCR2	15 months	May 8 2025	EPS -0.18 -15% Miss Revenue 5.9M -10% Miss	Aug 6 2025 (est.)	6 (B)	HOLD	UK
Genentech (RHHBY)	Immunosequencing	Illumina (ILMN) 10x Genomics (TXG)	18 months	May 7 2025	EPS -0.34 -8% Miss Revenue 41.5M +5% Beat	Aug 5 2025 (est.)	6 (B)	HOLD	USA
None	Immunology	CSL Behring (CSLLY) Grifols (GRFS)	36 months	May 9 2025	EPS 0.08 +20% Beat Revenue 81.9M +10% Beat	Aug 7 2025 (est.)	8 (A-)	BUY	USA
BMS (BMY) Merck (MRK)	Immun-Oncology	Incyte (INCY) Regeneron (REGN)	12 months	May 7 2025	EPS -0.22 -18% Miss Revenue 37.2M -5% Miss	Aug 5 2025 (est.)	5 (B-)	SELL	USA
Servier	Oncology	Servier Bristol Myers (BMY)	24 months	May 2 2025	EPS -1.65 -10% Miss Revenue 8.2M +15% Beat	Jul 31 2025 (est.)	7 (B+)	BUY	USA
None	Ophthalmology	Allergan (ABBY) Bausch (BHC)	18 months	May 7 2025	EPS -0.28 -12% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	6 (B)	HOLD	USA
GSK (GSK)	Neurodegenerative Diseases	Denali (DNL) Biogen (BIIB)	20 months	May 8 2025	EPS -0.45 -10% Miss Revenue 15.1M -8% Miss	Aug 6 2025 (est.)	6 (B)	HOLD	USA
Pfizer (PFE)	Cell Therapy	Arcellx (ACLY) Kite/Gilead (GILD)	18 months	May 7 2025	EPS -0.38 -7% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	6 (B)	HOLD	USA
Regeneron (REGN) Sanofi (SNY)	RNA Therapeutics	Arrowhead (ARWR) Ionis (IONS)	36 months	May 2 2025	EPS -0.75 +5% Beat Revenue 484.7M +12% Beat	Jul 31 2025 (est.)	9 (A)	STRONG BUY	USA
Fosun Pharma	Generics	Teva (TEVA) Viatris (VTRS)	N/A	May 8 2025	EPS 0.14 +10% Beat Revenue 659.2M +8% Beat	Aug 6 2025 (est.)	7 (B+)	BUY	USA
None	NASH	Madrigal (MDGL) Intercept (ICPT)	24 months	May 7 2025	EPS -0.85 -12% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	7 (B+)	BUY	USA
GSK (GSK)	Immunology	Regeneron (REGN) Amgen (AMGN)	18 months	May 9 2025	EPS -1.60 -15% Miss Revenue 10.4M -10% Miss	Aug 7 2025 (est.)	6 (B)	HOLD	USA
None	Neurodegenerative Diseases	Alector (ALEC) Denali (DNL)	12 months	May 7 2025	EPS -0.95 -20% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	5 (B-)	SELL	USA
Swedish Orphan (SOBI)	Ophthalmology	Regeneron (REGN) Roche (RHHBY)	30 months	May 7 2025	EPS -0.55 +8% Beat Revenue 162.5M +10% Beat	Aug 5 2025 (est.)	8 (A-)	BUY	USA
None	RNA Therapeutics	Amylam (ALNY) Moderna (MRNA)	18 months	May 8 2025	EPS -0.40 -10% Miss Revenue 2.1M -12% Miss	Aug 6 2025 (est.)	6 (B)	HOLD	USA
Kyowa Kirin	GI Disorders	Salix Ironwood (IRWD)	24 months	May 2 2025	EPS -0.09 +12% Beat Revenue 46.0M +15% Beat	Jul 31 2025 (est.)	8 (A-)	BUY	USA
Janssen (JNJ) Zai Lab	Immunology	Amgen (AMGN) Regeneron (REGN)	36 months	May 9 2025	EPS -1.05 +10% Beat Revenue 412.3M +12% Beat	Aug 7 2025 (est.)	9 (A)	STRONG BUY	Netherlands
None	Bacteriophage Therapy	ContraFect (CFRX)	12 months	May 7 2025	EPS -0.45 -15% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	5 (B-)	HOLD	USA
None	Dermatology	Incyte (INCY) Dermavant	24 months	May 8 2025	EPS -0.55 +10% Beat Revenue 21.6M +12% Beat	Aug 6 2025 (est.)	7 (B+)	BUY	USA
Pfizer (PFE)	PROTAC Technology	Amgen (AMGN) Kymera (KYMR)	18 months	May 7 2025	EPS -0.95 -10% Miss Revenue 25.3M +8% Beat	Aug 5 2025 (est.)	6 (B)	HOLD	USA
Gilead (GILD)	HBV Therapy	Arbutus (ABUS) Gilead (GILD)	12 months	May 8 2025	EPS -0.35 -12% Miss Revenue 6.2M -5% Miss	Aug 6 2025 (est.)	5 (B-)	SELL	USA
None	Endocrinology	Novo Nordisk (NVO) Pfizer (PFE)	30 months	May 2 2025	EPS -1.35 +8% Beat Revenue 95.4M +10% Beat	Jul 31 2025 (est.)	8 (A-)	BUY	Denmark
None	Neurodegenerative Diseases	Alector (ALEC) Annovis (ANVS)	12 months	May 7 2025	EPS -0.65 -15% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	5 (B-)	SELL	USA
None	Hereditary Angioedema	Takeda (TAK) CSL Behring	18 months	May 9 2025	EPS -0.45 -10% Miss Revenue 0.0M N/A	Aug 7 2025 (est.)	6 (B)	HOLD	USA
None	Pulmonary Sarcoidosis	Keros (KROS)	12 months	May 7 2025	EPS -0.25 -12% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	5 (B-)	SELL	USA
None	Ocular Oncology	Immunocore (IMCR)	18 months	May 8 2025	EPS -0.50 -8% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	USA
Otsuka	Lupus Nephritis	GSK (GSK) Calildatis (CALT)	24 months	May 2 2025	EPS -0.15 +12% Beat Revenue 50.3M +10% Beat	Jul 31 2025 (est.)	7 (B+)	BUY	Canada
Roche (RHHBY)	Antiviral Therapy	Gilead (GILD) Merck (MRK)	18 months	May 7 2025	EPS -0.55 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	6 (B)	HOLD	USA
None	Neurodegenerative Diseases	Biogen (BIIB) Alector (ALEC)	15 months	May 8 2025	EPS -0.15 -8% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	USA
Pfizer (PFE)	CNS Disorders	Jazz (JAZZ) Alkermes (ALKS)	30 months	May 7 2025	EPS -1.25 +10% Beat Revenue 74.8M +12% Beat	Aug 5 2025 (est.)	8 (A-)	BUY	USA
BMS (BMY)	Cardiomyopathy	Amylam (ALNY) Pfizer (PFE)	24 months	May 9 2025	EPS -0.95 -10% Miss Revenue 20.5M +8% Beat	Aug 7 2025 (est.)	7 (B+)	BUY	USA
None	Head and Neck Cancer	Incyte (INCY) Merck (MRK)	20 months	May 8 2025	EPS -0.40 -12% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	USA
None	Hereditary Angioedema	Astria (ATXS) Takeda (TAK)	24 months	May 7 2025	EPS -0.20 +8% Beat Revenue 92.4M +10% Beat	Aug 5 2025 (est.)	7 (B+)	BUY	USA
Pfizer (PFE) Verve (VERV)	Gene Editing	CRISPR (CRSP) Intellia (NTLA)	18 months	May 7 2025	EPS -1.05 -10% Miss Revenue 10.2M -5% Miss	Aug 5 2025 (est.)	6 (B)	HOLD	USA
Eisai (ESALY)	Neurodegenerative Diseases	Eli Lilly (LILY) Roche (RHHBY)	N/A	May 2 2025	EPS 3.85 +15% Beat Revenue 2.4B +5% Beat	Jul 31 2025 (est.)	8 (A-)	BUY	USA
None	Hematology	Amgen (AMGN) Jazz (JAZZ)	12 months	May 9 2025	EPS -0.10 -8% Miss Revenue 6.8M +10% Beat	Aug 6 2025 (est.)	6 (B)	HOLD	Israel
None	Oncology	Incyte (INCY) Merck (MRK)	15 months	May 7 2025	EPS -0.75 -12% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	6 (B)	HOLD	USA
None	Rare Diseases	Ultragenyx (RARE) Sarpta (SRPT)	N/A	May 2 2025	EPS 0.45 +12% Beat Revenue 650.3M +8% Beat	Jul 31 2025 (est.)	8 (A-)	BUY	USA
Pfizer (PFE)	mRNA Vaccines	Moderna (MRNA) Novavax (NVAX)	N/A	May 7 2025	EPS -1.05 +10% Beat Revenue 1.2B +5% Beat	Aug 5 2025 (est.)	8 (A-)	BUY	Germany
Roche (RHHBY)	Precision Oncology	Amgen (AMGN) Loxo (LLY)	30 months	May 7 2025	EPS -1.45 +8% Beat Revenue 85.6M +10% Beat	Aug 5 2025 (est.)	8 (A-)	BUY	USA
None	Neuropsychiatric Disorders	Axsome (AXSM) Jazz (JAZZ)	12 months	May 8 2025	EPS -0.65 -15% Miss Revenue 0.4M -20% Miss	Aug 6 2025 (est.)	5 (B-)	SELL	USA
None	Oncology	Immunocore (IMCR) Agenus (AGEN)	12 months	May 7 2025	EPS -0.35 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	5 (B-)	HOLD	USA
None	Oncology	Incyte (INCY) Merck (MRK)	12 months	May 8 2025	EPS -0.15 -12% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	5 (B-)	SELL	Israel
Nippon Shinyaku	Cardiomyopathy	BridgeBio (BBIO) Amylam (ALNY)	15 months	May 7 2025	EPS -0.30 -8% Miss Revenue 4.2M +10% Beat	Aug 5 2025 (est.)	6 (B)	HOLD	USA
Pfizer (PFE)	Oncology	Amgen (AMGN) Pfizer (PFE)	18 months	May 8 2025	EPS -0.65 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	USA
None	Cell Therapy	Alogene (ALLO) Arcellx (ACLY)	12 months	May 7 2025	EPS -0.25 -15% Miss Revenue 2.1M -10% Miss	Aug 5 2025 (est.)	5 (B-)	SELL	USA
None	Regenerative Medicine	Lineage Cell (LCTCX)	12 months	May 8 2025	EPS -0.20 -12% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	4 (C)	SELL	USA
None	Immunology	Regeneron (REGN) AnaptysBio (ANAB)	24 months	May 7 2025	EPS -0.60 -8% Miss Revenue 0.9M +5% Beat	Aug 5 2025 (est.)	7 (B+)	BUY	USA
Taiho Oncology	Oncology	Amgen (AMGN) Blueprint (BPMC)	18 months	May 8 2025	EPS -0.90 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	USA
None	Bladder Cancer	ImmuntyBio (IBRX) Merck (MRK)	24 months	May 7 2025	EPS -0.45 -8% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	7 (B+)	BUY	USA
None	Neurodegenerative Diseases	Annovis (ANVS) Alector (ALEC)	12 months	May 8 2025	EPS -0.25 -12% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	5 (B-)	SELL	USA
None	Biosimilars	Amgen (AMGN) Viatris (VTRS)	18 months	May 7 2025	EPS -0.15 +10% Beat Revenue 77.2M +8% Beat	Aug 5 2025 (est.)	6 (B)	HOLD	USA
None	Oncology	Regeneron (REGN) Bristol Myers (BMY)	12 months	May 8 2025	EPS -0.30 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	5 (B-)	SELL	USA
None	Ophthalmology	Regeneron (REGN) Bausch (BHC)	12 months	May 7 2025	EPS -0.15 -12% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	5 (B-)	HOLD	USA
Alogene (ALLO)	Cell Therapy	Alogene (ALLO) Arcellx (ACLY)	15 months	May 8 2025	EPS -0.35 -10% Miss Revenue 1.8M -5% Miss	Aug 6 2025 (est.)	5 (B-)	SELL	France
None	Oncology	Amgen (AMGN) Incyte (INCY)	12 months	May 7 2025	EPS -0.25 -8% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	5 (B-)	HOLD	USA
None	Hemophilia	CSL Behring Novo Nordisk (NVO)	20 months	May 8 2025	EPS -0.40 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	BUY	UK
None	Oncology	Blueprint (BPMC) Amgen (AMGN)	18 months	May 7 2025	EPS -0.55 -12% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	6 (B)	HOLD	USA
None	Neurodegenerative Diseases	Annovis (ANVS) Alector (ALEC)	15 months	May 8 2025	EPS -0.30 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	USA
None	Endocrinology	Pfizer (PFE) Novo Nordisk (NVO)	N/A	May 7 2025	EPS 0.25 +15% Beat Revenue 146.8M +10% Beat	Aug 5 2025 (est.)	8 (A-)	BUY	USA
BioMarin (BMRN) Endo Ventures	Rare Diseases	BioMarin (BMRN) Ultragenyx (RARE)	N/A	May 8 2025	EPS 0.45 +20% Beat Revenue 141.4M +15% Beat	Aug 6 2025 (est.)	8 (A-)	STRONG BUY	USA
None	Oncology	Amgen (AMGN) Merck (MRK)	18 months	May 7 2025	EPS -0.20 -8% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	6 (B)	BUY	USA
None	Oncology	Incyte (INCY) Blueprint (BPMC)	12 months	May 8 2025	EPS -0.25 -10% Miss Revenue 2.5M -5% Miss	Aug 6 2025 (est.)	5 (B-)	SELL	USA
None	Antimicrobial Therapy	Becton Dickinson (BDX)	18 months	May 7 2025	EPS -0.15 +10% Beat Revenue 0.8M +12% Beat	Aug 5 2025 (est.)	6 (B)	HOLD	USA
None	Endocrinology	Ascendis (ASND) Amgen (AMGN)	24 months	May 8 2025	EPS -0.85 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	7 (B+)	BUY	USA
Vertex (VRTX)	Gene Editing	Beam (BEAM) Intellia (NTLA)	24 months	May 7 2025	EPS -1.45 -10% Miss Revenue 0.5M -8% Miss	Aug 5 2025 (est.)	8 (A-)	BUY	Switzerland
Amgen (AMGN)	Oncology	Regeneron (REGN) Bristol Myers (BMY)	12 months	May 8 2025	EPS -0.15 -12% Miss Revenue 25.2M +10% Beat	Aug 6 2025 (est.)	5 (B-)	HOLD	USA
None	Cardiomyopathy	BridgeBio (BBIO) Amylam (ALNY)	24 months	May 7 2025	EPS -1.35 -10% Miss Revenue 0.9M -5% Miss	Aug 5 2025 (est.)	7 (B+)	BUY	USA
None	Pediatric Oncology	Blueprint (BPMC) Loxo (LLY)	18 months	May 8 2025	EPS -0.65 -8% Miss Revenue 8.2M +12% Beat	Aug 6 2025 (est.)	7 (B+)	BUY	USA
Biogen (BIIB) Sanofi (SNY)	Neurodegenerative Diseases	Alector (ALEC) Annovis (ANVS)	24 months	May 7 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	7 (B+)	BUY	USA
None	Vaccines	GSK (GSK) Moderna (MRNA)	N/A	May 8 2025	EPS 0.05 +15% Beat Revenue 75.6M +10% Beat	Aug 6 2025 (est.)	8 (A-)	BUY	USA
None	Gene Editing	CRISPR (CRSP) Beam (BEAM)	15 months	May 7 2025	EPS -0.80 -12% Miss Revenue 7.1M -5% Miss	Aug 5 2025 (est.)	6 (B)	HOLD	USA
Bayier Animal Health	Animal Health	Zoetis (ZTS) Merck Animal Health	N/A	May 7 2025	EPS 0.20 +12% Beat Revenue 1.2B +8% Beat	Aug 5 2025 (est.)	8 (A-)	BUY	USA
None	Oncology	Cullinan (CGEM) Incyte (INCY)	12 months	May 8 2025	EPS -0.25 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	5 (B-)	SELL	USA
None	Oncology	Blueprint (BPMC) Amgen (AMGN)	20 months	May 7 2025	EPS -0.45 -8% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	6 (B)	BUY	USA
None	Antiviral Therapy	Atesa (AVIR) Gilead (GILD)	18 months	May 8 2025	EPS -1.25 -10% Miss Revenue 17.8M -5% Miss	Aug 6 2025 (est.)	6 (B)	HOLD	USA
None	Aesthetics	Allergan (ABBY) Galderma	N/A	May 7 2025	EPS -0.10 +10% Beat Revenue 59.3M +12% Beat	Aug 5 2025 (est.)	7 (B+)	BUY	USA
Janssen (JNJ)	Oncology	Pfizer (PFE) Astellas (ALPMY)	15 months	May 8 2025	EPS -0.35 -12% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	5 (B-)	HOLD	Canada
Novartis (NVS)	Oncology	Blueprint (BPMC) Amgen (AMGN)	18 months	May 7 2025	EPS -0.25 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	6 (B)	BUY	USA
None	NASH	Akero (AKRO) Madrigal (MDGL)	20 months	May 8 2025	EPS -0.55 -8% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	BUY	USA
BMS (BMY) Sanofi (SNY)	AI-Driven Drug Discovery	Absci (ABSI) Recursion (RXRX)	18 months	May 7 2025	EPS -0.40 -10% Miss Revenue 10.5M -5% Miss	Aug 5 2025 (est.)	6 (B)	HOLD	UK
BMS (BMY) Roche (RHHBY)	Oncology	Amgen (AMGN) Pfizer (PFE)	N/A	May 7 2025	EPS 0.35 +15% Beat Revenue 425.2M +10% Beat	Aug 5 2025 (est.)	8 (A-)	BUY	USA
Arctic Vision	Ophthalmology	Apellis (APLS) Bausch (BHC)	12 months	May 8 2025	EPS -0.20 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	5 (B-)	HOLD	USA
None	Ophthalmology	Regeneron (REGN) Apellis (APLS)	18 months	May 7 2025	EPS -0.35 -8% Miss Revenue 11.8M +10% Beat	Aug 5 2025 (est.)	6 (B)	BUY	USA
UniQure (QURE)	Gene Therapy	Abeona (ABEO) Krystal (KRYS)	20 months	May 8 2025	EPS -0.65 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	USA
AstraZeneca (AZN)	Fibrosis	Akero (AKRO) Bbbio (ETNB)	12 months	May 7 2025	EPS -0.30 -12% Miss Revenue 36.4M -5% Miss	Aug 5 2025 (est.)	5 (B-)	SELL	USA
None	Rare Diseases	BioMarin (BMRN) Ultragenyx (RARE)	N/A	May 8 2025	EPS -0.05 +12% Beat Revenue 110.5M +10% Beat	Aug 6 2025 (est.)	8 (A-)	BUY	USA
None	Clinical Research Services	Labcorp (LH) IQVIA (IQV)	N/A	May 7 2025	EPS 0.25 +10% Beat Revenue 775.3M +8% Beat	Aug 5 2025 (est.)	7 (B+)	BUY	USA
None	Rare Diseases	Amicus (FOLD) BioMarin (BMRN)	18 months	May 8 2025	EPS -0.45 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	BUY	USA
None	Hematology	Jazz (JAZZ) Amgen (AMGN)	24 months	May 7 2025	EPS -0.10 +8% Beat Revenue 0.3M +10% Beat	Aug 5 2025 (est.)	7 (B+)	BUY	USA
Arcus Biosciences Merck (MRK) / HIV	Oncology	Amgen (AMGN) Pfizer (PFE)	N/A	May 7 2025	EPS 1.85 +15% Beat Revenue 6.7B +8% Beat	Aug 5 2025 (est.)	8 (A-)	BUY	USA
Gilead (GILD)	Immunology	Incyte (INCY) AbbVie (ABBV)	18 months	May 8 2025	EPS -0.35 -10% Miss Revenue 65.2M +5% Beat	Aug 6 2025 (est.)	6 (B)	HOLD	Belgium
None	Breast Cancer	SELLAS (SLS) Merck (MRK)	15 months	May 7 2025	EPS -0.25 -12% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	5 (B-)	HOLD	USA
None	Hematology	Jazz (JAZZ) Amgen (AMGN)	12 months	May 8 2025	EPS -0.15 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	5 (B-)	SELL	USA
Janssen (JNJ) AbbVie (ABBV)	Oncology	Amgen (AMGN) Regeneron (REGN)	N/A	May 7 2025	EPS 0.35 +12%				

None	Ophthalmology	Regeneron (REGN) Apellis (APLS)	12 months	May 8 2025	EPS -0.95 -12% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	5 (B-)	SELL	USA
None	Hematology	Geron (GERN) Amgen (AMGN)	20 months	May 7 2025	EPS -0.65 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	7 (B-)	BUY	USA
None	Oncology	Blueprint (BPMC) Incyte (INCY)	18 months	May 8 2025	EPS -0.55 -8% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	BUY	USA
None	Gene Therapy	Abeona (ABEO) 4DMT (FDMT)	N/A	May 7 2025	EPS 0.25 +15% Beat Revenue 70.3M +10% Beat	Aug 5 2025 (est.)	8 (A-)	BUY	USA
Sanofi (SNY)	Immunology	Regeneron (REGN) AnaptysBio (ANAB)	20 months	May 7 2025	EPS -0.75 -10% Miss Revenue 10.2M -5% Miss	Aug 5 2025 (est.)	7 (B-)	BUY	USA
Janssen (JNJ)	Cell Therapy	Allogene (ALLO) Arcellx (ACLX)	24 months	May 8 2025	EPS -0.35 +8% Beat Revenue 95.4M +12% Beat	Aug 6 2025 (est.)	8 (A-)	BUY	China
None	Ophthalmology	Eyenovia (EYEN) Apellis (APLS)	15 months	May 7 2025	EPS -0.45 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	6 (B)	HOLD	USA
Pfizer (PFE) Amgen (AMGN)	Drug Delivery	Halozyme (HALO) Catalent (CTLT)	N/A	May 8 2025	EPS 0.95 +10% Beat Revenue 45.7M +8% Beat	Aug 6 2025 (est.)	7 (B-)	BUY	USA
None	Pulmonary Diseases	Insmrd (INSM) United (UTHR)	18 months	May 7 2025	EPS -0.25 +8% Beat Revenue 4.5M +10% Beat	Aug 5 2025 (est.)	7 (B-)	BUY	USA
None	Rare Diseases	Amicus (FOLD) BioMarin (BMRN)	15 months	May 8 2025	EPS -0.35 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	USA
None	Cardiometabolic	AstraZeneca (AZN) Novo Nordisk (NVO)	18 months	May 7 2025	EPS -0.15 -8% Miss Revenue 1.2M +5% Beat	Aug 5 2025 (est.)	6 (B)	HOLD	USA
GSK (GSK)	Cell Therapy	Allogene (ALLO) Arcellx (ACLX)	15 months	May 8 2025	EPS -0.25 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	5 (B-)	HOLD	USA
None	NASH	Akero (AKRO) 89bio (ETNB)	24 months	May 7 2025	EPS -6.25 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	8 (A-)	BUY	USA
None	Cell Therapy	Allogene (ALLO) Celularity (CELJ)	18 months	May 8 2025	EPS -0.15 -8% Miss Revenue 7.2M -5% Miss	Aug 6 2025 (est.)	6 (B)	HOLD	Australia
Incyte (INCY)	Oncology	Amgen (AMGN) Regeneron (REGN)	12 months	May 7 2025	EPS -0.35 -12% Miss Revenue 10.8M -5% Miss	Aug 5 2025 (est.)	5 (B-)	SELL	USA
Janssen (JNJ)	Gene Therapy	Krystal (KTTA) 4DMT (FDMT)	15 months	May 8 2025	EPS -0.45 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	USA
Moderna (MRNA)	Gene Editing	CRISPR (CRSP) Editas (EDIT)	12 months	May 7 2025	EPS -0.35 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	5 (B-)	SELL	USA
None	Rare Diseases	Amicus (FOLD) BioMarin (BMRN)	24 months	May 7 2025	EPS -0.45 +8% Beat Revenue 77.5M +10% Beat	Aug 5 2025 (est.)	7 (B-)	BUY	USA
None	Hypertension	AstraZeneca (AZN) Novartis (NVS)	18 months	May 8 2025	EPS -0.55 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	USA
United (UTHR)	Diabetes	Novo Nordisk (NVO) Eli Lilly (LLY)	N/A	May 7 2025	EPS 0.05 +12% Beat Revenue 65.3M +10% Beat	Aug 5 2025 (est.)	7 (B-)	BUY	USA
None	CNS Disorders	Intra-Cellular (ITCI) Axsome (AXSM)	18 months	May 8 2025	EPS -0.25 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	USA
Ultragenyx (RARE)	Rare Diseases	Amicus (FOLD) BioMarin (BMRN)	18 months	May 7 2025	EPS -0.10 -8% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	6 (B)	HOLD	UK
None	CNS Disorders	Jazz (JAZZ) Axsome (AXSM)	12 months	May 8 2025	EPS -0.65 -10% Miss Revenue 8.2M -5% Miss	Aug 6 2025 (est.)	5 (B-)	SELL	USA
Janssen (JNJ)	Oncology	Amgen (AMGN) Incyte (INCY)	15 months	May 7 2025	EPS -0.25 -10% Miss Revenue 10.5M -5% Miss	Aug 5 2025 (est.)	5 (B-)	HOLD	USA
Incyte (INCY) Lilly (LLY)	Oncology	Regeneron (REGN) Blueprint (BPMC)	20 months	May 8 2025	EPS -0.85 -8% Miss Revenue 10.2M +5% Beat	Aug 6 2025 (est.)	7 (B-)	BUY	Netherlands
None	Oncology	MacroGenics (MGNX) Amgen (AMGN)	12 months	May 7 2025	EPS -0.15 -12% Miss Revenue 7.8M -5% Miss	Aug 5 2025 (est.)	5 (B-)	SELL	USA
None	Cardiovascular	Pfizer (PFE) Amgen (AMGN)	20 months	May 8 2025	EPS -0.45 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	7 (B-)	BUY	Netherlands
None	Proteomics	Seer (SEER) Somalogic	15 months	May 7 2025	EPS -0.15 -8% Miss Revenue 2.3M -5% Miss	Aug 5 2025 (est.)	5 (B-)	HOLD	USA
None	Oncology	Curis (CRIS) Cullinan (CGEM)	15 months	May 8 2025	EPS -0.35 -10% Miss Revenue 5.4M -5% Miss	Aug 6 2025 (est.)	6 (B)	HOLD	France
Gilead (GILD) Sanofi (SNY)	Oncology	Kura (KURA) Blueprint (BPMC)	18 months	May 7 2025	EPS -0.65 -8% Miss Revenue 12.3M +5% Beat	Aug 5 2025 (est.)	6 (B)	BUY	USA
Regeneron (REGN)	Gene Editing	CRISPR (CRSP) Editas (EDIT)	18 months	May 8 2025	EPS -1.35 -10% Miss Revenue 7.8M -5% Miss	Aug 6 2025 (est.)	7 (B-)	BUY	USA
None	Oncology	Amgen (AMGN) Pfizer (PFE)	18 months	May 7 2025	EPS -0.15 -8% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	6 (B)	HOLD	USA
None	Oncology	Blueprint (BPMC) Kura (KURA)	24 months	May 8 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	8 (A-)	BUY	USA
None	Diabetes Obesity	Eli Lilly (LLY) Amgen (AMGN)	N/A	May 7 2025	EPS 0.85 +15% Beat Revenue 10.2B +12% Beat	Aug 5 2025 (est.)	9 (A)	STRONG BUY	Denmark
Lilly (LLY) Genmab (GMAB)	Antibody Discovery	Ligand (LGND) Amgen (AMGN)	18 months	May 8 2025	EPS -0.15 -8% Miss Revenue 7.5M +5% Beat	Aug 6 2025 (est.)	6 (B)	HOLD	USA
None	Ophthalmology	Eyenovia (EYEN) Apellis (APLS)	18 months	May 7 2025	EPS -0.25 +8% Beat Revenue 15.3M +10% Beat	Aug 5 2025 (est.)	7 (B-)	BUY	USA
None	Oncology	Arvinas (ARVN) Mersana (MRSN)	18 months	May 8 2025	EPS -0.55 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	USA
None	Immunology	KalVista (KALV) CSL Behring	12 months	May 7 2025	EPS -0.65 -12% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	5 (B-)	SELL	USA
Pfizer (PFE)	Oncology	Kura (KURA) Nurix (NRX)	15 months	May 8 2025	EPS -0.45 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	USA
None	Health Insurance	UnitedHealth (UNH) Cigna (CI)	N/A	May 7 2025	EPS 0.15 +12% Beat Revenue 2.1B +10% Beat	Aug 5 2025 (est.)	7 (B-)	BUY	USA
None	Ophthalmology	Ocular (OCUJ) Eyenovia (EYEN)	15 months	May 8 2025	EPS -0.15 -8% Miss Revenue 10.2M +5% Beat	Aug 6 2025 (est.)	6 (B)	HOLD	USA
Pfizer (PFE)	Oncology	Mersana (MRSN) MacroGenics (MGNX)	N/A	May 7 2025	EPS 0.05 +10% Beat Revenue 45.3M +8% Beat	Aug 5 2025 (est.)	6 (B)	HOLD	USA
None	Vaccines	Pfizer (PFE) Moderna (MRNA)	24 months	May 8 2025	EPS -0.95 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	8 (A-)	BUY	USA
Merck (MRK)	Oncology	IO Biotech (IOBT) Mersana (MRSN)	15 months	May 7 2025	EPS -0.35 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	6 (B)	HOLD	USA
None	Oncology	IO Biotech (IOBT) PDS Biotech (PDSB)	12 months	May 7 2025	EPS -0.10 -10% Miss Revenue 1.2M -5% Miss	Aug 5 2025 (est.)	5 (B-)	SELL	USA
None	Rare Diseases	Amicus (FOLD) BioMarin (BMRN)	18 months	May 8 2025	EPS -0.05 +8% Beat Revenue 75.3M +10% Beat	Aug 6 2025 (est.)	6 (B)	HOLD	Netherlands
None	Gastroenterology	Takeda (TAK) Ironwood (IRWD)	18 months	May 7 2025	EPS -0.65 -8% Miss Revenue 7.5M +12% Beat	Aug 5 2025 (est.)	7 (B-)	BUY	USA
None	HAE	KalVista (KALV) CSL Behring	20 months	May 8 2025	EPS -0.55 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	Netherlands
None	Fibrosis	FibroGen (FGEN) 89bio (ETNB)	18 months	May 7 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	7 (B-)	BUY	USA
None	Regenerative Medicine	Celularity (CELJ) Mesoblast (MESO)	12 months	May 8 2025	EPS -0.25 -12% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	5 (B-)	SELL	Israel
None	Gene Editing	Intellia (NTLA) Editas (EDIT)	15 months	May 7 2025	EPS -0.35 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	6 (B)	HOLD	USA
BMS (BMY)	Neurodegenerative Diseases	Denali (DNLI) Alector (ALEC)	18 months	May 8 2025	EPS -0.95 -8% Miss Revenue 2.3M -5% Miss	Aug 6 2025 (est.)	6 (B)	BUY	USA
None	Rare Diseases	Amicus (FOLD) BioMarin (BMRN)	N/A	May 7 2025	EPS -1.25 -10% Miss Revenue 175.4M +8% Beat	Aug 5 2025 (est.)	7 (B-)	BUY	USA
Takeda (TAK)	Hematology	Keros (KROS) Geron (GERN)	20 months	May 8 2025	EPS -0.45 -8% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	7 (B-)	BUY	USA
CSL Behring	Gene Therapy	Krystal (KTTA) 4DMT (FDMT)	15 months	May 7 2025	EPS -1.15 -12% Miss Revenue 2.5M -5% Miss	Aug 5 2025 (est.)	6 (B)	HOLD	Netherlands
Mereo (MREO)	Rare Diseases	Amicus (FOLD) BioMarin (BMRN)	N/A	May 8 2025	EPS -1.85 -8% Miss Revenue 125.3M +10% Beat	Aug 6 2025 (est.)	8 (A-)	BUY	USA
None	Gene Therapy	uniQure (QURE) Krystal (KTTA)	20 months	May 7 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	7 (B-)	BUY	USA
Gilead (GILD) Taiho Oncology	Oncology	Amgen (AMGN) Merck (MRK)	18 months	May 8 2025	EPS -0.95 -8% Miss Revenue 45.2M +12% Beat	Aug 6 2025 (est.)	6 (B)	HOLD	USA
Sanofi (SNY) Bayer	Ophthalmology Immunology	Amgen (AMGN) Roche (RRHBRY)	N/A	May 7 2025	EPS 10.25 +15% Beat Revenue 3.2B +10% Beat	Aug 5 2025 (est.)	9 (A)	STRONG BUY	USA
Regeneron (REGN)	Oncology	IO Biotech (IOBT) PDS Biotech (PDSB)	15 months	May 8 2025	EPS -0.85 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	USA
None	Gene Therapy	uniQure (QURE) Rocket (RCKT)	18 months	May 7 2025	EPS -1.25 -8% Miss Revenue 15.3M -5% Miss	Aug 5 2025 (est.)	6 (B)	HOLD	USA
None	Hematology	Geron (GERN) Jazz (JAZZ)	18 months	May 8 2025	EPS -0.05 +8% Beat Revenue 36.4M +10% Beat	Aug 6 2025 (est.)	6 (B)	HOLD	USA
None	Oncology	Nuvalent (NUVL) Kura (KURA)	15 months	May 7 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	6 (B)	HOLD	USA
BMS (BMY)	Rare Diseases	Amicus (FOLD) Ultragenyx (RARE)	20 months	May 8 2025	EPS -0.65 -8% Miss Revenue 10.5M +5% Beat	Aug 6 2025 (est.)	7 (B-)	BUY	USA
Pfizer (PFE) Merck (MRK)	Royalty Financing	Ligand (LGND) Halozyme (HALO)	N/A	May 7 2025	EPS 0.95 +12% Beat Revenue 650.3M取得所M +8% Beat	Aug 5 2025 (est.)	8 (A-)	BUY	USA
None	Oncology	Kura (KURA) Nuvalent (NUVL)	24 months	May 8 2025	EPS -0.85 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	7 (B-)	BUY	USA
None	AI-Driven Drug Discovery	Excipienta (EXCI) Absci (ABSI)	18 months	May 7 2025	EPS -0.45 -8% Miss Revenue 15.2M +5% Beat	Aug 5 2025 (est.)	6 (B)	HOLD	USA
None	Rare Diseases	Amicus (FOLD) Ultragenyx (RARE)	24 months	May 8 2025	EPS -0.75 +8% Beat Revenue 28.4M +10% Beat	Aug 6 2025 (est.)	8 (A-)	BUY	USA
None	Rare Diseases	Amicus (FOLD) BioMarin (BMRN)	15 months	May 7 2025	EPS -0.35 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	6 (B)	HOLD	USA
Biogen (BIIB)	CNS Disorders	Jazz (JAZZ) Axsome (AXSM)	18 months	May 7 2025	EPS -1.65 -8% Miss Revenue 12.3M +5% Beat	Aug 5 2025 (est.)	6 (B)	HOLD	USA
None	Cell Therapy	Allogene (ALLO) Lyell (LYEL)	20 months	May 8 2025	EPS -0.35 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	USA
Pfizer (PFE)	Gene Therapy	uniQure (QURE) Rocket (RCKT)	12 months	May 8 2025	EPS -0.15 -0% Miss Revenue N/A	Aug 7 2025 (est.)	5 (B-)	SELL	USA)
None	Gene Therapy	Ultragenyx (RARE) Rocket (RCKT)	18 months	May 8 2025	EPS -0.65 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	USA
None	Rare Diseases	Rhythm (RYTM) Amicus (FOLD)	24 months	May 7 2025	EPS -0.25 +8% Beat Revenue 0.0M N/A	Aug 5 2025 (est.)	7 (B-)	BUY	USA
Akero Inc.	Oncology	Amgen (AMGN) Merck (MRK)	20 months	May 8 2025	EPS -0.05 -8% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	7 (B-)	BUY	USA
None	Allergy	KalVista (KALV) CSL Behring	18 months	May 7 2025	EPS -0.15 +10% Beat Revenue 5.3M +12% Beat	Aug 5 2025 (est.)	7 (B-)	BUY	USA
None	CNS Disorders	Sage (SAGE) Jazz (JAZZ)	20 months	May 8 2025	EPS -0.55 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	BUY	USA
None	Immunology	Regeneron (REGN) AnaptysBio (ANAB)	18 months	May 7 2025	EPS -0.85 -8% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	6 (B)	HOLD	USA
None	Cell Therapy	Lyell (LYEL) Allogene (ALLO)	15 months	May 8 2025	EPS -0.35 -10% Miss Revenue 2.3M -5% Miss	Aug 6 2025 (est.)	6 (B)	HOLD	USA
None	Immunology	Argenx (ARGX) Regeneron (REGN)	N/A	May 7 2025	EPS 0.05 +12% Beat Revenue 65.4M +10% Beat	Aug 5 2025 (est.)	8 (A-)	BUY	USA
None	Oncology	Kura (KURA) Nuvalent (NUVL)	12 months	May 8 2025	EPS -0.25 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	5 (B-)	SELL	USA
None	Oncology	Relay (RLAY) Nuvalent (NUVL)	15 months	May 7 2025	EPS -0.35 -8% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	6 (B)	HOLD	USA
None	Immunology	Argenx (ARGX) Regeneron (REGN)	20 months	May 8 2025	EPS -0.65 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	7 (B-)	BUY	USA
None	Obesity	Novo Nordisk (NVO) Eli Lilly (LLY)	24 months	May 7 2025	EPS -0.25 -8% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	8 (A-)	BUY	USA
None	Immunology	Argenx (ARGX) Regeneron (REGN)	18 months	May 8 2025	EPS -0.45 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	7 (B-)	BUY	USA
None	Respiratory	Insmrd (INSM) Chiesi	24 months	May 7 2025	EPS -0.35 +8% Beat Revenue 0.0M N/A	Aug 5 2025 (est.)	7 (B-)	BUY	UK
None	Oncology	Kura (KURA) Relay (RLAY)	15 months	May 8 2025	EPS -0.25 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	USA
Neurocrine (NBIX)	Neurodegenerative Diseases	Denali (DNLI) Alector (ALEC)	18 months	May 7 2025	EPS -0.45 -8% Miss Revenue 12.3M +5% Beat	Aug 5 2025 (est.)	6 (B)	HOLD	USA
GSK (GSK)	Rare Diseases	Amicus (FOLD) Ultragenyx (RARE)	18 months	May 8 2025	EPS -0.25 -10% Miss Revenue 15.2M -5% Miss	Aug 6 2025 (est.)	7 (B-)	BUY	USA
Neurocrine (NBIX)	CNS Disorders	Sage (SAGE) Jazz (JAZZ)	24 months	May 7 2025	EPS -0.65 -8% Miss Revenue 0.3M N/A	Aug 5 2025 (est.)	7 (B-)	BUY	Canada
None	Endocrinology	MannKind (MNKD) Corcept (CORT)	N/A	May 8 2025	EPS -0.10 +10% Beat Revenue 45.3M +12% Beat	Aug 6 2025 (est.)	6 (B)	HOLD	USA
None	Oncology	Pfizer (PFE) Kura (KURA)	15 months	May 7 2025	EPS -0.85 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	6 (B)	HOLD	USA
None	Oncology	Kura (KURA) Relay (RLAY)	12 months	May 8 2025	EPS -0.35 -12% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	5 (B-)	SELL	USA
Ligand (LGND) Vir Biotechnology	Royalty Financing	Ligand (LGND) Royalty Pharma (RPRX)	N/A	May 7 2025	EPS 0.15 +10% Beat Revenue 15.9M +8% Beat	Aug 5 2025 (est.)	7 (B-)	BUY	USA
None	CNS Disorders	Jazz (JAZZ) Axsome (AXSM)	N/A	May 8 2025	EPS -0.15 +8% Beat Revenue 12.5M +10% Beat	Aug 6 2025 (est.)	6 (B)	HOLD	USA
None	Immunology	Argenx (ARGX) Regeneron (REGN)	18 months	May 8 2025	EPS -0.65 -10% Miss Revenue 0.0M N/A	Aug 7 2025 (est.)	6 (B)	HOLD	USA
Jazz (JAZZ) GSK (GSK)	Oncology	Amgen (AMGN) Merck (MRK)	24 months	May 7 2025	EPS -0.45 -8% Miss Revenue 15.3M +5% Beat	Aug 5 2025 (est.)	7 (B-)	BUY	Canada

Comments
Trading below cash value; strong partnerships; pipeline advancing but revenue growth limited]](https://x.com/Hedgebullish/status/1932116713451209027/)](https://x.com/brooks_david2/status/1930461578958106742/)](https://x.com/
Limited revenue; cash runway constrained; EB-101 pivotal data critical
AI-driven platform gaining traction; early-stage pipeline; partnerships strong
HBV focus; limited near-term catalysts; cash runway tight
Strong commercial traction with DAYBUE; pipeline expansion promising
High-risk cell therapy; limited cash runway; early-stage pipeline
Promising cell therapy pipeline; strong partnership with Gilead
Small-cap dermatology focus; limited cash runway; pipeline early-stage
High-risk T-cell therapy; cash runway constrained; GSK partnership key
clonoSEQ commercialized; diagnostic focus; stable but slow growth
Strong commercial growth; expanding manufacturing capacity; financially stable
High-risk immuno-oncology; cash runway tight; pipeline speculative
PYRUKYND commercialized; pipeline advancing; stable cash position
Ophthalmology focus; reproxalap pivotal data key; cash runway limited
Neuro focus; GSK partnership; early-stage pipeline
Allogeneic cell therapy; high-risk; Pfizer partnership key
Strong RNAi portfolio; multiple approved drugs; robust pipeline]](https://www.biopharmcatalyst.com/news/2020/argenx-argx-shares-rally-on-positive-late-stage-data-34-alnylam-alny-lumasiran-pd-ufa-set-for-december)
Stable generics business; limited innovation; financially sound
NASH focus; EFX pivotal data critical; strong cash position
Immunology pipeline; GSK partnership; moderate risk
High-risk neuro focus; limited cash runway; early-stage pipeline]](https://finance.yahoo.com/quote/ANVS/)
Strong commercial traction with SYOVRE; pipeline expanding
RNAi focus; early-stage pipeline; moderate risk
Strong commercial growth; IBSRELA sales ramping; stable finances]](https://www.biopharmcatalyst.com/company/ABDX)
VYVGART strong commercial success; robust pipeline; financially stable]](https://www.biopharmcatalyst.com/news/2020/argenx-argx-shares-rally-on-positive-late-stage-data-34-alnylam-alny-lumasiran-pd-ufa-set-for-decem
Small-cap bacteriophage focus; limited cash runway; high-risk pipeline
ZORYVE commercial traction; expanding indications; stable finances]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-argt/arcutis-biotherapeutics/valuation)
PROTAC platform innovative; early-stage pipeline; Pfizer partnership key
HBV focus; limited cash runway; high-risk early-stage pipeline
Strong commercial portfolio; TransCon platform promising; financially stable
High-risk neuro focus; limited cash runway; pivotal data critical
Early-stage HAE focus; moderate risk; cash runway sufficient
Small-cap pulmonary focus; limited cash runway; high-risk pipeline
Ocular oncology niche; early-stage pipeline; moderate risk
LUPKYNIS commercial success; stable finances; expanding indications
Antiviral focus; early-stage pipeline; Roche partnership key
Neuro focus; high-risk pipeline; pivotal data critical
Strong commercial traction; AUVELITY sales growing; robust pipeline
Promising cardiomyopathy pipeline; strong partnerships; stable finances
Early-stage oncology focus; moderate risk; cash runway sufficient
ORLADEYO commercial success; pipeline advancing; stable finances
Gene editing platform; early-stage pipeline; strong partnerships
Established neuro portfolio; LEQEMBI sales growing; financially stable
APHEXDA recently approved; commercial ramp-up critical; limited cash runway]](https://www.nasdaq.com/articles/nj-acquires-mnta-fda-strikes-down-bmrms-gene-therapy-bmrms-gene-on-track-tptx-on-watch)
Oncology focus; early-stage pipeline; moderate risk
Strong rare disease portfolio; VOXZOGO sales robust; financially stable]](https://www.nasdaq.com/articles/nj-acquires-mnta-fda-strikes-down-bmrms-gene-therapy-bmrms-gene-on-track-tptx-on-watch)
COMIRNATY global success; mRNA oncology pipeline promising; financially stable
Precision oncology leader; AYVAKIT sales growing; strong pipeline
IGALMI approved but limited uptake; high-risk pipeline; cash runway constrained
Oncology focus; early-stage pipeline; limited cash runway
Small-cap oncology; high-risk pipeline; cash runway constrained
Cardiomyopathy focus; early-stage pipeline; partnership with Nippon Shinyaku
Oncology focus; early-stage pipeline; moderate risk
High-risk cell therapy; limited cash runway; early-stage pipeline
Pre-clinical regenerative medicine; high-risk; limited cash runway
Promising immunology pipeline; barzolvolimab data key; stable finances]](https://finance.yahoo.com/quote/CLDX/)
Oncology focus; early-stage pipeline; Taiho partnership
Bladder cancer focus; promising phase 3 data; stable cash position
High-risk neuro focus; limited cash runway; early-stage pipeline
UDENYCA commercialized; biosimilar focus; moderate growth
High-risk oncology; limited cash runway; pivotal data critical
Ophthalmology focus; early-stage pipeline; cash runway constrained]](https://finance.yahoo.com/quote/CRVS/)
High-risk cell therapy; limited cash runway; early-stage pipeline]](https://finance.yahoo.com/quote/CLLS/)
Oncology focus; early-stage pipeline; cash runway limited
Hemophilia focus; promising pipeline; stable cash position
Oncology focus; early-stage pipeline; moderate risk
Neuro focus; early-stage pipeline; moderate cash runway
KORLYM strong commercial performance; pipeline advancing; financially stable
Strong commercial growth with FIRDAPSE; AGAMREE sales ramping; financially stable]](https://stockanalysis.com/stocks/cprx/)
Oncology focus; early-stage pipeline; promising data
High-risk oncology; limited cash runway; early-stage pipeline
DEFENCATH recently approved; commercial ramp-up critical; moderate cash runway
Endocrinology focus; paltusotine pivotal data key; stable cash position
Casgevvy approved; strong Vertex partnership; expanding pipeline
Oncology focus; early-stage pipeline; Amgen partnership key
Aficanten pivotal data critical; strong cash position; commercial potential
Ojemda recently approved; pediatric focus; stable cash runway
Neuro focus; strong partnerships; promising pipeline
HEPLISAV-B strong commercial performance; stable finances
Gene editing focus; early-stage pipeline; cash runway limited]](https://ir.edtbiomedicine.com/static-files/b5d9235d-41cc-4266-8526-b5d8618c431b)
Strong animal health portfolio; recent product approvals; financially stable
High-risk oncology; limited cash runway; early-stage pipeline
Oncology focus; early-stage pipeline; stable cash position
Antiviral focus; early-stage pipeline; moderate cash runway
Jeuneau strong aesthetics market performance; expanding indications
Oncology focus; early-stage pipeline; Janssen partnership
Oncology focus; naporafenib pivotal data key; Novartis partnership
NASH focus; promising phase 2 data; stable cash position
AI-driven platform; early-stage pipeline; strong partnerships
Cabometyx strong commercial performance; robust pipeline
Mydcambi approved; commercial ramp-up critical; limited cash runway
YUTIQ commercialized; EYP-1901 data key; moderate cash runway
Gene therapy focus; early-stage pipeline; stable cash position
High-risk fibrosis focus; limited cash runway; pivotal data critical
Strong rare disease portfolio; Galafold sales robust; financially stable
CRO services stable; strong client base; financially sound
Rare disease focus; losmapimod pivotal data key; stable cash position
Rytelo recently approved; commercial ramp-up critical; stable finances
Strong HIV and oncology portfolio; robust commercial revenue; recent FDA trial halts a concern]](https://www.tradingview.com/symbols/NASDAQ-GILD/)
Immunology focus; JYSELECA approved in EU; limited US presence
Breast cancer vaccine; early-stage pipeline; cash runway constrained]](https://macrotrends.net/stocks/charts/GLS/greenwich-lifesciences/stock-price-history)
High-risk hematology; uproleselan pivotal data critical; limited cash runway]](https://finance.yahoo.com/quote/GLYC/)
Strong oncology portfolio; Darzalex sales robust; financially stable
NASH focus; early-stage pipeline; moderate cash runway
ENHANZE platform drives revenue; strong partnerships; financially stable
High-risk oncology; limited cash runway; Gilead partnership key
WAKIX strong commercial performance; expanding indications; financially stable
Ocaliva commercialized; NASH focus; stable but competitive market
Oncology focus; promising pipeline; strong partnerships
KIMMTRAK commercial success; expanding oncology pipeline
High-risk oncology; limited cash runway; early-stage pipeline
Oncology focus; early-stage pipeline; stable cash position
Immunology focus; promising phase 3 data; stable cash position
Rare disease focus; early-stage pipeline; Sanofi partnership
Jakafi strong commercial performance; Opzelura expanding; robust pipeline
Arikayce commercialized; TPIP data key; strong growth potential
Respiratory focus; stable royalty revenue; financially sound
Rare disease focus; early-stage pipeline; moderate cash runway
Amtagvi recently approved; commercial ramp-up critical; stable finances
Caplyta strong commercial traction; expanding indications; financially stable
High-risk antiviral focus; limited cash runway; early-stage pipeline
Oncology focus; early-stage pipeline; promising data
Strong CNS portfolio; Xywav and Epidiolex driving growth; financially stable
High-risk immunology; limited cash runway; early-stage pipeline
HAE focus; sebetralstat pivotal data key; moderate cash runway
Immunology focus; commercial-stage; stable cash position

High-risk ophthalmology; limited cash runway; pivotal data critical
Hematology focus; promising pipeline; stable cash position
Oncology focus; ziftomenib data key; moderate cash runway
Vyjuvek commercial success; expanding gene therapy pipeline
Immunology focus; Sanofi partnership; stable cash position
Carvykti strong commercial traction; Janssen partnership; robust pipeline[(https://datafct.com/symbol-list.txt)]
Ophthalmology focus; early-stage pipeline; moderate cash runway
Capitol platform drives revenue; stable royalty stream; financially sound
Yutrepia recently approved; commercial ramp-up critical; moderate cash runway
Rare disease focus; early-stage pipeline; moderate cash runway
Impella commercialized; LX9211 data key; moderate cash runway
Cell therapy focus; early-stage pipeline; GSK partnership
Rezdiffra first-in-class NASH therapy; commercial ramp-up critical; strong cash position[(https://finance.yahoo.com/quote/BBIO/)](https://www.evaluate.com/node/18478&)
Cell therapy focus; regulatory hurdles; moderate cash runway[(https://datafct.com/symbol-list.txt)]
High-risk oncology; limited cash runway; early-stage pipeline[(https://datafct.com/symbol-list.txt)]
Gene therapy focus; Janssen partnership; moderate cash runway
High-risk gene editing; limited cash runway; early-stage pipeline
Livmarli commercial success; volixibat data key; stable finances
Hypertension focus; early-stage pipeline; moderate cash runway
Afrezza commercialized; expanding indications; financially stable[(https://db.cs.cmu.edu/files/data/stocks/history.txt)]
Psychedelc therapy focus; early-stage pipeline; high-risk high-reward
Rare disease focus; setrusumab pivotal data key; Ultragenyx partnership[(https://investorshub.advn.com/Biotech-Values:1418)]
Zlmany commercialized; high-risk pipeline; limited cash runway[(https://finance.yahoo.com/quote/BTAU/)](https://github.com/pthoang/TDT4310_project/blob/master/FinNum_training_rebuild.csv)
Oncology focus; early-stage pipeline; Janssen partnership[(https://finance.yahoo.com/quote/BTAU)]
Oncology focus; zenocutuzumab promising; stable cash position
High-risk oncology; limited cash runway; early-stage pipeline[(https://github.com/pthoang/TDT4310_project/blob/master/FinNum_training_rebuild.csv)]
Cardiovascular focus; obicetrapib pivotal data key; stable cash position
Proteomics platform; pre-clinical stage; moderate cash runway
Oncology focus; NBTXR3 pivotal data key; moderate cash runway[(https://finance.yahoo.com/quote/NBTX/?itr=1)]
Oncology focus; early-stage pipeline; strong partnerships
Gene editing focus; NTLA-2001 promising; Regeneron partnership
Oncology focus; early-stage pipeline; moderate cash runway
Oncology focus; promising pipeline; strong cash position
Ozempic and Wegovy market leaders; robust pipeline; financially stable[(https://finance.yahoo.com/quote/NVO)]
Antibody platform; early-stage partnerships; moderate cash runway
Dextenza commercialized; AXPAXLI data key; moderate cash runway
Oncology focus; early-stage pipeline; moderate cash runway
High-risk immunology; limited cash runway; regulatory hurdles
Oncology focus; early-stage pipeline; Pfizer partnership[(https://finance.yahoo.com/quote/NBTX/?itr=1)]
Health insurance focus; strong growth; not a traditional biotech
Upneeq commercialized; niche ophthalmology market; moderate cash runway
Nerlynx commercialized; limited growth potential; stable finances
Vaccine focus; VAX-24 promising; strong cash position
Oncology focus; early-stage pipeline; Merck partnership[(https://investorshub.advn.com/Biotech-Values:1418)]
High-risk oncology; limited cash runway; early-stage pipeline
Joenja commercialized; rare disease focus; moderate cash runway
Voquezna recently approved; commercial ramp-up critical; moderate cash runway
HAE focus; deucricitbant pivotal data key; stable cash position
Fibrosis focus; bexotegast promising; stable cash position[(https://finance.yahoo.com/quote/RNA)]
High-risk regenerative medicine; limited cash runway; early-stage pipeline
Gene editing focus; early-stage pipeline; moderate cash runway
Neuro focus; PRX012 promising; BMS partnership
Emflaza commercialized; Upstaza US approval pending; stable finances
Hematology focus; rusferide pivotal data key; stable cash position
Gene therapy focus; AMT-130 data key; CSL partnership
Strong rare disease portfolio; multiple approved drugs; financially stable
Gene therapy focus; RP-L201 promising; stable cash position[(https://investorshub.advn.com/Biotech-Values:1418)]
Oncology focus; Gilead partnership; moderate cash runway
Eylea and Dupixent market leaders; robust pipeline; financially stable[(https://bullishbears.com/biotech-stocks-list)]
Oncology focus; early-stage pipeline; Regeneron partnership
Gene therapy focus; RGX-121 data key; moderate cash runway
Rezlidhia commercialized; niche hematology market; moderate cash runway
Oncology focus; early-stage pipeline; moderate cash runway
Rare disease focus; AOC 1001 promising; stable cash position[(https://finance.yahoo.com/quote/RNA4)]
Strong royalty portfolio; stable revenue stream; financially sound
Oncology focus; early-stage pipeline; strong cash position[(https://investorshub.advn.com/Biotech-Values:1418)]
AI-driven platform; early-stage pipeline; moderate cash runway
Inolvee commercial success; expanding pipeline; stable finances
Rare disease focus; early-stage pipeline; moderate cash runway[(https://www.biopharmcatalyst.com/news/2024/rezolute-zlt-phase-2-data-plant-plrx-preclinical-data)]
Zurzuwae commercializing; CNS focus; Biogen partnership key
Cell therapy focus; early-stage pipeline; stable cash position
High-risk gene therapy; limited cash runway; Pfizer partnership
Gene therapy focus; early-stage pipeline; moderate cash runway
DCCR nearing approval; rare disease focus; strong cash position[(https://finance.yahoo.com/quote/SLNO)]
Oncology focus; ivonescimab promising; Akso partnership
Nerfly recently approved; commercial ramp-up critical; stable finances
CNS focus; STK-001 promising; stable cash position
Immunology focus; early-stage pipeline; moderate cash runway
Cell therapy focus; early-stage pipeline; moderate cash runway[(https://www.benzinga.com/general/biotech/21/09/22947673/the-daily-biotech-pulse-illy-regeneron-ink-covid-19-drug-deal-with-us-regulatory-setback-for-ca)]
Briumvi strong commercial traction; expanding indications; financially stable
High-risk oncology; limited cash runway; early-stage pipeline
Oncology focus; early-stage pipeline; moderate cash runway
Immunology focus; TOUR006 promising; stable cash position
VK2735 promising in obesity; strong cash position; high market interest
Immunology focus; VRDN-001 pivotal data key; moderate cash runway
Ohtuvayre recently approved; commercial ramp-up critical; stable finances
Oncology focus; early-stage pipeline; moderate cash runway
Neuro focus; early-stage pipeline; Neurocrine partnership
Rare disease focus; WVE-006 promising; GSK partnership
Azatrionant pivotal data key; CNS focus; strong cash position[(https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/estimating-the-intrinsic-value-of-xenon-pharmaceuticals-ir)]
Multiple commercial products; stable revenue; niche endocrinology market
Oncology focus; FDA lifted clinical hold on azenoserib; moderate cash runway[(https://finance.yahoo.com/news/biotech-stock-roundup-gild-nvlt-132100903.htm?src=rss)]
High-risk oncology; limited cash runway; early-stage pipeline
Royalty-based model; stable revenue; Q1 2025 revenue beat expectations[(https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xoma/xoma-royalty/news/xoma-royalty-first-quarter-2025-earnings-beats-expecta)]
Azstanya commercialized; niche CNS market; stable finances
Immunology focus; obexelimab promising; phase 3 data expected soon[(https://seekingalpha.com/article/4773527-zonas-differentiated-b-cell-targeting-drug-with-q3-of-2025-catalyst)]
Oncology focus; zanidatamab pivotal data key; strong partnerships